Search clinical trials for: Valsartan + HCTZ

Total 705 results

Novartis

Completed

8-week Study to Evaluate Safety and Efficacy of Various Combinations of Valsartan, HCTZ, and Amlodipine in Patients With Moderate to Severe Hypertension

Hypertension

United States
Novartis

Completed

Pharmacokinetic Drug Interaction Study Following Co-administration of Valsartan, Hydrochlorothiazide and Amlodipine in Patients With Hypertension

Hypertension

India
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Compared to Valsartan Monotherapy or Hydrochlorothiazide Monotherapy in Elderly (>70) With Mild-moderate Hypertension.

Hypertension

United States
Novartis

Terminated

Antialbuminuric Effects of Valsartan and Lisinopril

Hypertension | Early Diabetic Nephropathy

Switzerland
Novartis

Completed

Valsartan/Amlodipine As Compared to Losartan Treatment in Stage 2 Systolic Hypertension (EXALT)

Stage 2 Systolic Hypertension

United States
Novartis

Completed

Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension

Hypertension

United States
Novartis

Completed

Effects of Blood Pressure Reduction on High Sensitivity C-Reactive Protein (hsCRP)

Hypertension
Novartis Pharmaceuticals

Completed

The Effects of Sacubitril/Valsartan on Cardiac Oxygen Consumption and Efficiency of Cardiac Work in Heart Failure Patients (TurkuPET)

Heart Failure

Finland
Novartis Pharmaceuticals
Baker Heart and Diabetes Institute

Completed

Valsartan Intensified Primary Care Reduction of Blood Pressure Study (VIPER-BP)

Hypertension

United States, Australia
Novartis

Completed

Efficacy of Valsartan/Hydrochlorothiazide Versus Amlodipine and Hydrochlorothiazide in Patients Hypertension

Hypertension

United States
Novartis Pharmaceuticals

Completed

Safety/Efficacy of Valsartan/Hydrochlorothiazide Combination Compared to Hydrochlorothiazide in Obese Hypertensive Adults

Hypertension

United States
Novartis

Completed

Antiproteinuric Effect of Valsartan and Lisinopril

Hypertension | Diabetic Nephropathy

Switzerland
Federico II University

Completed

Efficacy and Safety of Valsartan Plus Hydrochlorothiazide in Patients With Slight Hypertension and Target Organ Damage

Hypertension | Ventricular Remodeling | Erectile Dysfunctions

Italy
Qingdao Central Hospital

Not yet recruiting

Sacubitril/Valsartan Versus Valsartan for Hypertensive Patients With Acute Myocardial Infarction

Myocardial Infarction | Hypertension

China
Vanderbilt University Medical Center

Completed

The Effects of Renin Inhibition on Fibrinolytic Balance and Endothelial Function

High Blood Pressure

United States
Damanhour University
Tanta University

Completed

Sacubitril/Valsartan Versus Valsartan in Heart Failure

Heart Failure

Egypt
Yuhan Corporation

Completed

Pharmacokinetic Drug Interaction Between Rosuvastatin and Valsartan

Hypertension | Hyperlipidemia

Korea, Republic of
Novartis

Completed

A Safety and Tolerability Study of the Combination of Aliskiren/Valsartan in Patients With High Blood Pressure, Followed by Long-term Safety and Tolerability of Aliskiren, Valsartan and Hydrochlorothiazide.

Hypertension

United States, Canada, Germany, Netherlands
Novartis Pharmaceuticals

Completed

Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)

Heart Failure With Preserved Ejection Fraction (HFpEF)

United States, Canada
University of Missouri-Columbia

Completed

Optimal HCTZ Cessation for Diagnosis of Hyperparathyroidism

Hyperparathyroidism

United States
University of Alabama at Birmingham
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals

Cardiovascular Diseases | Diabetes Mellitus | Insulin Sensitivity/Resistance | Metabolic Disease | Energy Expenditure | Metabolism | Natriuretic Peptides

United States
Novartis Pharmaceuticals

Completed

Dose Response of Valsartan on Sitting Systolic Blood Pressure in Children 6 Months - 5 Years of Age With High Blood Pressure

Hypertension

Sweden, Belgium, Hungary, India, Italy, Poland, Turkey, United States, Brazil, France, South Africa
University of Alabama at Birmingham
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis (PRECISION-BP)

Cardiovascular Diseases | Hypertension | Obesity | Nocturnal Blood Pressure | Natriuretic Peptides | Renin-Angiotensin-Aldosterone System

United States
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease

Diabetic Kidney Disease

China
Novartis Pharmaceuticals

Completed

Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications (Navigator)

Diabetes Mellitus, Type 2

Austria, Argentina, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, Denmark, Ecuador, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Italy, Malaysia, Mexico, Netherlands, Norway, Peru, Poland, Russian Federation and more
Novartis

Completed

A Clinical Study With Aliskiren Alone or in Combination Therapy With Diuretic Hctz in Venezuelan Hypertensive Patients. (ANDROMEDA)

High Blood Pressure

Venezuela
Forest Laboratories

Completed

Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension

Stage 2 Hypertension | Stage 1 Hypertension

United States
Viatris Inc.

Not yet recruiting

A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions

Chronic Heart Failure
Novartis

Completed

A Safety and Efficacy Trial of the Combination of Aliskiren / Hydrochlorothiazide (HCTZ)(300/12.5 mg and 300/25 mg) Compared to Aliskiren 300 mg in Hypertensive Patients

Hypertension

United States, Germany
Novartis

Completed

Safety/Efficacy of Combo Therapy With Aliskiren & Hydrochlorothiazide vs Therapy With Hydrochlorothiazide Alone in Patients With Hypertension

Hypertension

United States, Germany
LanZhou University

Unknown

Effect of Fully Blocking Type 1 Angiotensin Receptor on Target Organ Damage of Postmenopausal Hypertensive Women

Hypertension
Novartis Pharmaceuticals

Completed

Role of Sacubitril/Valsartan in Improving Provider Performance in Managing Heart Failure Under Medicare Alternative Payment Models

Heart Failure

United States
Hannover Medical School
DLR German Aerospace Center

Withdrawn

Influences of Angiotensin-neprilysin Inhibition on Sympathetic Activity in Heart Failure (ARNI-Sy)

Heart Failure

Germany
The Children's Hospital of Zhejiang University...

Unknown

Study on the Treatment of Children With Purpura Nephritis With Huaiqihuang Granules

Henoch Schönlein Purpura Nephritis

China
Kitakyushu-Tsuyazaki Hospital

Completed

Valsartan Optimal Therapy Against Elevated Home Blood Pressure Research（VOYAGER）Study

Hypertension

Japan
Duke University
National Heart, Lung, and Blood Institute (NHLBI)

Completed

EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study) (HFN-LIFE)

Heart Failure

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Valsartan and Amlodipine in Patients With Essential Hypertension

Essential Hypertension

Japan
Boryung Pharmaceutical Co., Ltd
Chonbuk National University Hospital; Samsung Medical Center; Asan Medical Center and other collaborators

Completed

A Clinical Study to Evaluate Efficacy and Safety of Fimasartan/Hydrochlorothiazide Combination-therapy

Essential Hypertension

Korea, Republic of
Bio-innova Co., Ltd

Not yet recruiting

Sacubitril 97 mg and Valsartan 103 mg Film-coated Tablets Relative to Entresto 97 mg/103 mg Film-coated Tablets

Healthy Subjects
University of Zurich
Novartis Pharmaceuticals

Completed

Differential Vascular and Endocrine Effects of Valsartan/Sacubitril in Heart Failure With Reduced Ejection Fraction (VASCEND)

Heart Failure

Switzerland
Guangdong Provincial People's Hospital

Unknown

Efficacy and Safety of Sacubitril/Valsartan in Maintenance Hemodialysis Patients With Heart Failure (ESARHD-HF)

Heart Failure | Hemodialysis Complication

China
Dong-A University

Completed

The Impact of Dose of Angiotensin-receptor Blocker Valsartan and Genetic Polymorphism on the Post-MI Ventricular Remodeling (VALID)

Myocardial Infarction

Korea, Republic of
Novartis

Completed

A Study of Valsartan Administered Once Daily Versus Twice Daily, in Patients With Stable, Chronic Heart Failure

Chronic Heart Failure

United States
University of Texas Southwestern Medical Center
Novartis Pharmaceuticals

Withdrawn

Regression of Fatty Heart by Valsartan Therapy

Metabolic Syndrome | Lipotoxicity

United States
University of South Carolina
Duke University; Kilimanjaro Christian Medical Centre, Tanzania

Completed

Does Preference-based HIV Testing Increase Uptake in High Risk Populations? (DCE-IMPACT)

HIV Testing

United States, Tanzania
Novartis Pharmaceuticals

Completed

A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients (PARALLAX)

Heart Failure With Preserved Ejection Fraction

Colombia, Romania, United States, Austria, Belgium, Estonia, Turkey, Germany, Netherlands, Italy, Spain, Thailand, Argentina, France, Bulgaria, Hungary, Israel, Peru, Lithuania, Guatemala, India, Russian Federation, Denmark, Mexico, Slo... and more
VA Office of Research and Development

Completed

Diuretic Comparison Project (DCP)

Hypertension

United States, Puerto Rico
University of Leipzig

Active, not recruiting

Hemodynamic Effects of ARNI on Noninvasive Pressure-volume Analysis in Patients With Chronic Heart Failure (ARNI-PVA)

Heart Failure With Reduced Ejection Fraction

Germany
Novartis Pharmaceuticals

Completed

Patient Reported Outcomes inVestigation Following Initiation of Drug Therapy With Entresto (Sacubitril/Valsartan) in Heart Failure (PROVIDE-HF)

Heart Failure, Systolic

United States
Novartis Pharmaceuticals

Completed

Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction Patients: a Real World Study in India

Heart Failure

India

3

Subscribe